Resection Depth of Underwater Versus Conventional Endoscopic Mucosal Resection for Intermediate-Sized Colorectal Tumors.

Am J GastroenterolJan 9, 2026 (epub)
Clinical ResearchGastroenterologyOpen access

Yuzuru Tamaru, Akihiro Miyakawa, Haruhisa Shimura et al.

✦ AI-curated · Sources linked

In 30 seconds

This multicentre, noninferiority randomised trial compared resection depth with underwater and conventional endoscopic mucosal resection (UEMR and CEMR) for 10–20 mm colorectal tumors at four Japanese institutions. Among 217 randomly assigned patients, mean depth was 1,688.9 ± 1,510.0 μm with UEMR and 1,432.3 ± 1,294.2 μm with CEMR; the mean difference was 256.6 μm (95% confidence interval: -119.9-633.1 μm; P = 0.18). The authors concluded that UEMR achieved comparable resection depth, although the reported interval does not establish noninferiority against the prespecified margin.

Key findings

  • Mean resection depth was 1,688.9 ± 1,510.0 μm with UEMR versus 1,432.3 ± 1,294.2 μm with CEMR; mean difference 256.6 μm (95% confidence interval: -119.9-633.1 μm; P = 0.18).
  • For cecal and ascending-colon lesions, depth was 1,822.4 ± 1,469.7 μm with UEMR versus 1,096.5 ± 1,007.6 μm with CEMR (P = 0.01).
  • For superficially shaped lesions, depth was 1,238.7 ± 862.2 μm with UEMR versus 731.6 ± 376.1 μm with CEMR (P < 0.01).

Why it matters

Resection depth is relevant to the technical adequacy of endoscopic removal. This trial provides a direct randomised comparison for intermediate-sized colorectal tumors and suggests that UEMR can achieve depths comparable to CEMR overall, with greater depths in some subgroups. The findings inform understanding of the technique but do not, by themselves, establish superiority or a change in clinical outcomes.

What to keep in mind

The primary outcome was resection depth, a procedural measure; the abstract does not report clinical outcomes such as recurrence. The confidence interval for the overall difference extends beyond the prespecified 400 μm noninferiority margin.

Source

Published in Am J Gastroenterol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.